Evista, also called raloxifene, is a medication that's used to reduce the risk of invasive breast cancer in post-menopausal women. It's also used to reduce the risk of spinal fractures related to ...

Eli Lilly ($LLY) is staring down the barrel of its Evista patent expiration. And Tuesday, Teva Pharmaceutical Industries ($TEVA) won FDA approval to load the bullet ...

Hopes that the osteoporosis drug Evista would offer women a clearly safer alternative to tamoxifen for breast cancer prevention have been dashed by findings from a long-awaited study, researchers say.

Eli Lilly agreed to plead guilty to a misdemeanor and pay a $36 million fine in connection with off-label promotion of osteoporosis drug Evista (raloxifene). The plea is for one misdemeanor violation ...

The STAR (Study of Tamoxifen and Raloxifene) trial, one of the largest breast cancer prevention trials ever conducted, showed that five years of Evista is as effective as tamoxifen in lowering risk of ...

A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major victory for the company, says an analyst who closely follows the ...

WASHINGTON, Sept 1 (Reuters) - Eli Lilly & Co won a patent battle protecting its osteoporosis drug Evista on Wednesday, as an appeals court declined to toss out a permanent injunction preventing ...

Eli Lilly got a bit of vindication on Tuesday after a judge placed a 10-day restraining order on generic drugmaker Teva Pharmaceuticals, which tried to violate Lilly's patents. The two drugmakers are ...